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I~  Novel steroids with anti-inflammatory activity that stimulate 
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E Nicoletti 4, R. Pieters 5, C. Ahlem 1 , J. Frincke 1 , C. Reading 1 . 1HollisEden 
Pharmaceuticals', 2VA Hospital, San Diego, CA; 3Case Western Reserve University 
School of Medicine, Cleveland, OH, USA; 4University of Camnia School of 
Medicine, Catania, Italy; 5IRAS-Immunotoxicology, Utrecht University, The 
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Pulmonary inflammation and abnormal eicosanoid production are important patho- 
logic features of CE 16o,~romoepiandrosterone (HE2000) is a synthetic steroid 
with demonstrated anti-inflammatory activity in man. HE2000 and its metabolite 5o, 
androstan-3f3,16o,-diol-17-one (HE3151) significantly (p<0.05) reduced numbers 
of neutrophils and pleural exudate volumes (-50%) in the murine model of 
carrageenan i duced pleurisy. Both compounds increased survival (>25%) in an 
LPS murine shock model and reduced cell numbers (-30%) and accelerated the 
maturation (increased lymphocytes) of infiltrates in a murine model of LPS induced 
lung injury. HE3151 significantly (p <0.005) reduced chronic inflammation in 
delayed-type hypersensitivity responses. In the gut corrected 6fir ~ mouse model 
of P aeruginosa lung infection, HE2000 significantly (p < 0.05) reduced bacterial 
burden and accelerated the maturation of cellular infiltrates (p 0.056). In the 
reporter antigen popliteal lymph node assay (immune toxicity) neither HE2000 
nor HE3151 were found to be immune-suppressive. Ongoing studies hypothesize 
normalization of eicosanoid metabolism. Treatment of CF and other diseases 
associated with chronic inflammation of the lung with HE2000, HE3151, or another 
closely related analog, may provide anti-inflammatory benefit to patients without 
immune suppressive side effects. 
5. Immunology pulmonology 
1~ Dosing tobramycin in the inhalation therapy of Cystic Fibrosis - 
a comparison of LC PLUS used in breath triggered mode and 
EFLOW RAPID 
O. Pechtold 1 , J. Stegemann 2, J. Paulukat 2, K. Sommerer 1 . lInamed GmbH & 6'o. 
KG, Robert-Koch-Allee 29, 82131 Gauting; 2Inj~ctoPharm Arzneimittel GmbH, 
Von-Humboldt-Str 1, 64646 Heppenheim, Germany 
Introduction: This in vitro study compared the dosing of tobramycin with LC 
PLUS used in breath triggered mode and EFLOW RAPID. Therefore, the to- 
bramycin commonly used for inhalation in Germany, GERNEBCIN, was nebulised 
in different doses. 
Methods: The nebulisation of differently concentrated tobramycin solutions: 
(1) 80mg/2ml, (2) 160mg/4ml and (3) 320mg/4ml with the EFLOW RAPID 
was examined by breath simulation measurements. As a reference the nebulisation 
with the LC PLUS was performed with and without breath triggered inhalation. 
Especially the most relevant nebuliser-/drug-parameters like respirable dosage of 
tobramycin RD [mg] and time of inhalation IT [min] were ascertained. 
Results: The generated RD with EFLOW RAPID and LC PLUS for all nebulised 
doses of tobramycin was (1) 8.5/8.5, (2) 28.3/27.3, (3) 57/54.2; the IT was 
(1) 1.3/4.2, (2) 3.9/11, (3) 4.3/11.5. If an inspiration triggered nebulisation is 
performed with the LC PLUS, the RD rises up to 22%. The EFLOW RAPID 
is not able to nebulise residual volumes and therefore (1) 56, (2) 80 and (3) 143 mg 
of tobramycin were wasted. 
Summary: The EFLOW RAPID is generating the same RD for tobramycin 
solutions of different concentrations a the LC PLUS. IT with EFLOW RAPID 
is much shorter but the breath triggered nebulisation with LC PLUS enables 
significantly higher RDs. The potential of the EFLOW's membrane technology to 
reduce the necessary drug-dose is not used by the "RAPID"-model. By increasing 
the volume of the GERNE13CIN-solution, this problem can be antagonised partly. 
The dosage for nebulised GERNE13CIN can be oriented on the study data at hand. 
I •  Reduction of drug-dose and therapy-costs in the inhalation 
therapy with high dose tobramycin 
R Brand 1, S. H~iul3ermann 1 , t3. Miillinger 3, A. Fischer 3, t3. Wachall 2, 
J. Stegemann 2. lInamed GmbH, Robert-Koch-Alice 29, 82131 Gauting; 
2Inj~ctoPharm Arzneimittel GmbH, Von-Humboldt-Str 1, 64646 Heppenheim; 
3Activaero GmbIt, Wohraer Stt: 37, 35285 Gemi~nden/Wohra, Germany 
Aims: The pseudomonas effective inhalation in cystic fibrosis with high dose 
tobramycin (TOBI 2 x 300 mg/day) is very cost intensive. The in vivo study at 
hand shows how to realise a considerable r duction of drug dose and thus also a 
reduction of therapy costs without decreasing the tobramycin lung deposition. 
Methods: Following a randomised cross-over scheme, twelve subjects inhaled 
300mg/5ml (TOBI) with a LC PLUS and 160mg/4ml (GERNEBCIN) with a 
LC STAR, which is flow and breath controlled by means of the AKITA-system. 
The intrapulmonal drug depositions was ascertained by gamma-szintigraphy. Fur- 
thermore FEV 1 and serum levels of tobramycin were determined 1 h after each 
inhalation. 
Results: The depositions of tobramycin in the lungs was 41±12 mg (TO13I/LC 
PLUS) and 43±5 mg (GERNEBCIN/AKITA). The tobramycin serum levels were 
0.39±0.21mg/L after TO13I and 0.56±0.19mg/L after GERNE13CIN. None of 
these treatments showed a striking decline of FEV 1 after inhalation, which lasted 
comparably about 13 rain. The costs for each inhalation, based on German pharmacy 
sales prices, were about 19e for GERNE13CIN and 59e for TO13I. 
Conclusions: The inhalation-system AKITA allows a maximum drug utilisation 
and a high accuracy in dosing the drug. Therefore, the lower dosage of tobramycin 
formulation, GERNE13CIN for inhalation, is as sufficient as TO13I inhalation to 
reach the necessary depositions in the lung. This reduces the oropharyngeal drug 
exposure and thus the potential of bronchial irritations. Using GERNE13CIN/AKITA 
for high dose tobramycin halation helps to save therapy costs in Germany of about 
80e each day. 
1• Effects of tobramycin solution for inhalation in patients with 
Pseudomonas aeruginosa chronic colonization 
A. Sol~, A. Pastor, J. Cerdn, E. Monte, M. Gaspar. Adult CF and Lung Transplant 
Unit. Universitary Hospital La Fe, Valencia, Spain 
Background: Pseudomonas aeruginosa (PA) chronic colonization is a highly 
significant event in the course of CF as it heralds an increase in the morbid- 
mortality. In fact, the lung function of a CF patient declines by about 2 3% per 
year. Inhaled antibiotics are the recommended therapy, as parenteral dministration 
cannot eradicate lung infection. Tobramycin solution for inhalation (TSI) allows 
higher concentration to be delivered irect to the lungs without systemic toxicity. 
Methods: From the 120 patients in follow up in the Adult CF Unit, it was selected 
a cohort of patients >14 years with TIS therapy during at least a year, from mild 
to severe pulmonary disease, no colonized by other resistant microorganisms, PA
chronic colonized and a decrease of lung function with other inhaled antibiotic 
therapies and no resistance nor hypersensitivity to tobramycin. FEV1, microbiology 
and weight have been analyzed one year before and after up to 3 years in TSI 
therapy. 
Results: It was included 27 patients: age (meaniDS): 25±5.37 years (15 35 y); 
70% male, 30% female; mean FEV1 at baseline: 2.83L (66.51% predicted). 
5 patients had FEV1 >75% and the rest, between 25 and 75%. 2 patients were 
colonized by Aspergillus fumigatus during TSI therapy. There was no selection 
of other multirresistant microorganisms. Decreasing trend of FEV1 was reverted 
with TSI therapy with a significant improvement of the lung function (p < 0.001). 
FEVI% increased 9.58%, 4.5% and 5.1% over baseline after 1, 2 and 3 years of 
therapy. There was a light increase of weight and few adverse vents. 
Conclusion: TSI therapy improves ignificantly the lung function in a short and 
medium term in CF patients with bad response to other suppressive therapies. 
